In December 2019, an outbreak of pneumonia of unknown origin was reported in Wuhan,
Hubei Province, China. Pneumonia cases were epidemiologically linked to the Huanan …

We review aspects of the antibody response to SARS-CoV-2, the causative agent of the
COVID-19 pandemic. The topics we cover are relevant to immunotherapy with plasma from …

Background and objectives COVID‐19 convalescent plasma (CCP) has been used,
predominantly in high‐income countries (HICs) to treat COVID‐19; available data suggest …

Convalescent plasma (CP) from blood donors with antibodies to severe acute respiratory
syndrome coronavirus 2 may benefit patients with COVID-19 by providing immediate …

Background: The COVID-19 pandemic, caused by a novel coronavirus termed SARS-CoV-2,
has spread quickly worldwide. Convalescent plasma (CP) obtained from patients following …

The world is striving against the severe crisis of the COVID-19 pandemic. Healthcare
professionals are struggling to treat their patients based on nonspecific therapies. Amidst …

In Winter 2020, Italy, and in particular the Lombardy region, was the first country in the
Western hemisphere to be hit by the COVID-19 pandemic. Plasma from individuals …

Objective To assess the safety and efficacy of convalescent plasma (CP) transfusion in
elderly people with moderate to severe coronavirus disease 2019 (COVID-19) living in a …

Background Little is known about the quality and potential impacts of the guidelines for
coronavirus disease 2019 (COVID-19) management. Methods We systematically searched …

Background Convalescent plasma has been used for a long time for the treatment of various
infectious diseases. The principle is to collect antibody-containing plasma from recovered …